SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (Nasdaq: SABS) is a clinical-stage biopharmaceutical company focused on developing human polyclonal antibodies using its proprietary genetically engineered cattle platform. The company went public in October 2021 through a business combination with Hennessy Capital Investment Corp. IV, a blank-check vehicle sponsored by Hennessy Capital Group. Operating in the biotechnology sector, SAB Biotherapeutics has advanced multiple candidates targeting infectious disease and other immunological indications. The company filed an 8-K with the SEC on July 7, 2026, under accession number 0001193125-26-296936. For the full filing history, ownership data, and real-time event tracking on SABS and hundreds of other de-SPAC companies, sign up for SpacDesk.